Introduction
Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease with a variable clinical course and prognosis [1]. This heterogeneity poses enormous challenges to diagnostic, medical, and therapeutic progress [2]. SLE has a remarkable female predominance, with nearly 10 female patients for each male patient. The incidence ranges from 0.3 to 31.5 cases per 100,000 people per year [3]. Although it is present in all ethnicities, it is more prevalent in non-Caucasians. SLE is uncommon in Africa, despite the fact that the prevalence of the disease is higher among people of African heritage in Europe and the United States [4, 5].
The manifestations of SLE are linked to the presence of numerous autoantibodies (Ab), which are responsible for the development and accumulation of immune complexes (ICs), in addition to other immunological processes [6]. Constitutional, mucocutaneous, and musculoskeletal (MSK) symptoms are the earliest and most commonly reported complaints among SLE patients. Nevertheless, this disease can have an impact on any organ, including the skin, hematologic, renal, neuropsychiatric (NP), cardiovascular, and/or pulmonary systems [1].
Anzeige
MSK symptoms, such as arthritis and arthralgia, are frequent SLE manifestations. Over the course of the disease, 53–95% of patients report MSK manifestations and joint involvement, and up to 60% during disease flares [7, 8]. SLE has a substantial impact on health related quality of life (HRQoL) [9]. SLE-related involvement in the MSK system may have a major impact on HRQoL [10].
In spite of the high frequency of MSK manifestations, there are several aspects of these manifestations that need further clarification. There have only been a few studies that have investigated the impact of MSK symptoms on HRQoL in SLE patients.
So, our aim of this study was to evaluate the MSK symptoms experienced by SLE patients and determine how those symptoms relate to their HRQoL.
Patients and methods
Study design and setting
This is a cross-sectional study that was conducted between April and September 2022 at the Rheumatology and Immunology Unit (inpatient and outpatient) in the Mansoura University Hospital in Egypt, which is an urban tertiary hospital. Patients who were diagnosed with SLE were included in the study in a sequential manner. All patients met the systemic lupus international collaborating clinics classification criteria [11] or the new 2019 EULAR/ACR Classification Criteria for SLE [12]. No selection process resulted in the collection of more severe cases. Individuals who were less than 18 years old, had a history of malignancy, or suffered from any other chronic rheumatic, musculoskeletal, or neurological disorder were not allowed to participate in the study from the very beginning. Each researcher held an organized in-person encounter with each patient, verbally presenting the items using simple and clear language. This approach enables more complex issues to be explored than the self-administered style and provides more detailed explanations of the queries.
Anzeige
Ethical consideration
This study was conducted in accordance with the principles outlined in the Helsinki Declaration [13], and the Institutional Research Board of the Faculty of Medicine at Mansoura University provided its approval (Approval No: R.23.04.2145) to the study protocol before it was carried out.
Sample size calculation
This calculation of the sample size was carried out using G*Power. The outcome of interest was determined to be the prevalence of MSK disorders among SLE patients, and it was approximately 85% over the course of the disease [7]. The effect size was calculated to be 0.1, the alpha error was calculated to be 0.05, and the power of the study was 0.9. Hence, the total number of individuals in the sample was determined to be 93.
Questionnaire structure
The questionnaire included already validated questionnaires and other questions about the sociodemographic, clinical, and therapeutic data. A “yes or no” response was provided to most questions, and most of them were close ended. The questions were crafted to be straightforward and without any misinterpretation. The participants were informed that their participation in the survey is fully voluntary, and they were also given the option to decline participation. All personal information, including their names and contact information, will be kept strictly confidential and used solely for scientific study. By signing the consent form, they stated that they were willing to participate in the study.
Sociodemographic data
The following sociodemographic data were obtained from the participants: age, gender, material status, education level, employment, residency, and socioeconomic status.
Clinical data of lupus
Participants were questioned on their age when they received their initial diagnosis of lupus, the length of time they had been living with the disease, and whether or not they had a previous history of renal transplantation, nephritis, dialysis, seizures, strokes, or psychiatric diagnoses. Then, clinical evaluation was done, and the SLE disease activity index (SLEDAI) [14] was assessed. On the basis of SLEDAI scores, the following activity categories have been defined: no activity (SLEDAI = 0), mild activity (SLEDAI = 1 to 5), moderate activity (SLEDAI = 6 to 10), high activity (SLEDAI = 11 to 19), and very high activity (SLEDAI ≥ 20) [15].
SLE therapeutic data
Therapeutic data were obtained from the participants. They were questioned regarding the medications that they take for the management of their condition, such as corticosteroids, antimalarials, azathioprine, methotrexate, mycophenolate, or any other immunosuppressive drugs or biologics.
Musculoskeletal discomfort form
The Nordic Musculoskeletal Questionnaire (NMQ-E), which is valid and reliable, was essentially used to assess the existence and distribution of MSK symptoms such as ache, pain, discomfort, and numbness carefully at different body areas. The NMQ-E questionnaire comes with a picture that the patient can look at and pinpoint the approximate location of the portions of the body that he is having trouble with [16].
Short-form McGill pain questionnaire (SF-MPQ)
It is a valid and reliable evaluation that is quicker and simpler to utilize in clinical research; it was used to measure the pain sensory intensity [17]. The Arabic version of the SF-MPQ was utilized for this research because it has been shown to be reliable and valid among Arabic-speaking patients [18]. It included 15 descriptors, four of which were affective and eleven of which were sensory. Each descriptor was graded on a scale from 0 (none) to 1 (mild) to 2 (moderate) to 3 (severe) on an intensity scale. The Present Pain Intensity (PPI) index of the standard McGill Pain Questionnaire (MPQ) and a Visual Analogue Scale (VAS) were both incorporated in the Short Form McGill Pain Questionnaire (SF-MPQ) in order to assess the experience of pain intensity [19]. The total score on the questionnaire ranged from 0 to 45 on the Pain Rating Index (PRI), including (Affective Subscore: 0/12 & Sensory Subscore: 0/33), from 0 to 5 on the PPI, and from 0 to 10 centimeters on the VAS [20].
Anzeige
Lupus quality of life (Lupus QoL)
This is the most commonly studied SLE-specific HRQoL score, developed and validated in SLE adults from the United Kingdom [21]. It is comprised of 34 questions derived from SLE patients and organized into eight domains, including physical health, emotional health, body image, pain, planning, fatigue, intimate relationships, and burden on others. The questions were based on the patient’s experience in the previous four weeks, and responses were given on a 5-point Likert scale (0–4, where 0 means always and 4 means never). A summary Lupus QoL score of 0 to 100 was presented, with higher values indicating better HRQoL, 0 representing the worst HRQoL, and 100 representing the best HRQoL. The respondent took less than 10 min to complete.
Statistical analysis
In order to do analysis on the collected data, the Statistical Package for Social Science (SPSS) version 22 program was utilized. When presenting quantitative data, we used means and standard deviations (SD) for parametric variables and median (min-max) for nonparametric variables. When presenting qualitative data, we used percentages and numbers. The Shapiro-Wilk test was carried out in order to ascertain whether or not the variable distribution was normal. The Kruskal-Wallis test was utilized in order to analyze the nonparametric data.
Results
The study comprised 103 SLE patients recruited from an Egyptian rheumatology and immunology clinic. Their mean age was 30.81 ± 9.44 years. There were a total of 86 females and 17 males (F: M:5:1). Sociodemographic characteristics are illustrated in Table 1. Among them, 59.2% were married, 62.1% had graduated from college, 58.3% originated from urban areas, and 80.6% had a socioeconomic standing that was moderate. Only 13.6% of participants were current smokers, while 22.3% of participants exercised regularly.
Table 1
Sociodemographic data of the studied SLE patients (n = 103)
Variable mean ± SD, n (%) | Total SLE patients (n = 103) |
|---|---|
Age (years) | 30.81 ± 9.44 |
Sex | |
Male Female | 17 (16.5) 86 (83.5) |
Marital status | |
Single Married Widow Divorced | 36 (35.0) 61 (59.2) 3 (2.9) 3 (2.9) |
Living alone | 10 (9.7) |
Education level | |
Not educated Primary school Secondary school High school Graduate Postgraduate | 3 (2.9) 3 (2.9) 7 (6.8) 23 (22.3) 64 (62.1) 3 (2.9) |
Residence | |
Rural Urban | 43 (41.7) 60 (58.3) |
Employment status | |
Not employed Employed Retired Student | 47 (45.6) 40 (38.8) 2 (1.9) 14 (13.6 |
Socioeconomic status | |
Low Moderate High | 15 (14.6) 83 (80.6) 5 (4.9) |
Life habits | |
Smoking Exercise practice | 14 (13.6) 23 (22.3) |
Treatment payment system | |
Health insurance State expense Patient expense | 10 (9.7) 61 (59.2) 32 (31.1) |
Anzeige
Clinical and therapeutic data of the participants are illustrated in Table 2. The mean age at lupus diagnosis was 24.82 ± 8.49 years, with a median disease duration of 4 years. Only 11.7% had biopsy-proven nephritis, and 2.9% were on maintenance hemodialysis. According to SLEDAI, 35.9% had mild disease activity, whereas 37.9% had moderate disease activity. treatment received in the following descending frequency: corticosteroids (80.6%), antimalarials (54.4%), azathioprine (52.4%), mycophenolate mofetil (22.3%), methotrexate (20.4%), and biologics (8.7%).
Table 2
Clinical and therapeutic data of the study SLE patients (n = 103)
Variable mean ± SD, n (%), median (min-max) | Total SLE patients (n = 103) |
|---|---|
Age at diagnosis (years) | 24.82 ± 8.49 |
Diseases duration (years) | 4 (1–39) |
Clinical manifestations | |
Psychiatric diagnosis | 11 (10.7) |
Seizures | 11 (10.7) |
Stroke | 6 (5.8) |
Biopsy proven nephritis | 12 (11.7) |
Dialysis | 3 (2.9) |
Disease activity (SLEDAI) | |
No Mild Moderate Sever | 19 (18.4) 37 (35.9) 39 (37.9) 8 (7.8) |
SLE medication classes | |
Steroids | 83 (80.6) |
Antimalarials | 56 (54.4) |
Azathioprine | 54 (52.4) |
Mycophenolate Mofetil | 23 (22.3) |
Methotrexate | 21 (20.4) |
Biologics | 9 (8.7) |
The frequency of MSK symptoms (ache, pain, discomfort, and numbness) in the study SLE patients is shown in Fig. 1. According to the body regions, the maximum number of patients reported pain in the right and left wrist and hand (64.1%, 63.1%, respectively), followed by right knee (62.1%) and lower back (57.3%), followed by the left and right shoulder (54.4%, 53.4%, respectively) and left knee (53.4%). Ribs (39.8%) and left hip and thigh (36.9%) were the least common symptoms.
Fig. 1
MSK symptoms among the studied SLE patients (n = 103)
×
![]()
Anzeige
According to the Nordic MSK Questionnaire, almost all the studied SLE patients reported MSK symptoms (96.1%). As indicated in Table 3, approximately one-fourth (25.2%) described at least five bodily sites of MSK symptoms, while 70.9% had more than five sites of MSK symptoms. The length of time that patients experienced MSK symptoms varied, with 49.5% reporting MSK symptoms for more than three months.
Table 3
Duration and number of MSK symptoms per individual in the study SLE patients (n = 103)
Variable n (%) | Total SLE patients (n = 103) |
|---|---|
MSK symptoms | |
No symptoms | 4 (3.9) |
At least 5 body sites | 26 (25.2) |
> 5 body sites | 73 (70.9) |
Duration of MSK symptoms | |
< 6 weeks | 27 (26.2) |
6 weeks − 3 months | 25 (24.3) |
≥ 3 months | 51 (49.5) |
The SF-MPQ scores of the participants in the study are outlined in Table 4. Most of the patients described the pain as discomforting (40.8%), while only 3.9% described it as excruciating. The pattern of pain is predominantly intermittent (61.2%), whereas it is continuous in only 13.6% of cases. The median value of VAS was 6.
Table 4
Short-Form McGill Pain score in the study SLE patients (n = 103)
Variable mean ± SD, n (%), | Total SLE patients (n = 103) |
|---|---|
Sensory component | 13 (0–30) |
Affective component | 5 (0–12) |
Total Descriptor | 19 (0–42) |
Present Pain Intensity (PPI) index | |
No pain | 4 (3.9) |
Mild | 20 (19.4) |
Discomforting | 42 (40.8) |
Distressing | 16 (15.5) |
Horrible | 17 (16.5) |
Excruciating | 4 (3.9) |
Pattern of pain | |
Repeated after a short period of time | 22 (21.4) |
Intermittent | 63 (61.2) |
Continuous | 14 (13.6) |
Visual analogue scale | 6 (0–10) |
The study employed the scores of lupus QOL domains according to the distribution of MSK symptoms. As indicated in Table 5, patients with MSK symptoms scored significantly worse in all domains than those without symptoms. In addition, the QoL scores of patients with more than five body sites of MSK symptoms were significantly lower than those of patients with fewer than five sites of MSK symptoms.
Table 5
Distribution of Lupus QOL domains according to the distribution MSK symptoms in the study SLE patients (n = 103)
Variable | Total | Musculoskeletal symptoms | P | ||
|---|---|---|---|---|---|
No n = 4 | ≤ 5 discomforts n = 26 | > 5 discomforts n = 73 | |||
Physical health | 43.75 (0-100) | 100 (87.50–100 | 50 (6.25–100) | 37.5 (0-100) | 0.001* |
Pain | 50 (0-100) | 100 (100–100) | 58.33 (0-100) | 41.67 (0-100) | 0.001* |
Planning | 50 (0-100) | 100 (100–100) | 50 (0-100) | 50 (0-100) | 0.002* |
Intimate relationships | 75 (0-100) | 100 (100–100) | 75 (0-100) | 50 (0-100) | 0.002* |
Burden to others | 50 (0-100) | 100 (100–100) | 58.33 (0-100) | 50 (0-100) | < 0.001* |
Emotional health | 45.83 (0-100) | 100 (95.83–100) | 56.25 (0-100) | 41.67 (0-87.50) | < 0.001* |
Body image | 50 (0-100) | 100 (75–100) | 65 (5-100) | 45 (0-100) | 0.002* |
Fatigue | 43.75 (0-100) | 100 (87.5–100) | 50 (0-100) | 37.5 (0-93.75) | 0.001* |
Discussion
To the best of our knowledge, this is the first detailed study of MSK problems experienced by SLE patients that utilizes the Nordic MSK Questionnaire. The study included those diagnosed with SLE, and the results provide information regarding the link between MSK symptoms and HRQoL in these patients. The present study revealed that SLE patients have a high prevalence of MSK symptoms and that the elevated prevalence of these symptoms is also associated with a decline in their HRQoL. The findings of this study indicated that SLE patients struggle with a variety of symptoms that may influence their perception of their position in life and impede their physical, intimate, and emotional health.
In the current study, almost all of the SLE patients (96.1%) had MSK symptoms. MSK manifestations are among the most prevalent characteristics of SLE, both in terms of initial diagnosis and long-term treatment [22]. MSK manifestations of SLE can be the first symptom to appear in up to half of all SLE patients and can impact up to 95% of patients at some point during the course of the disease [8, 23]. As a result, MSK manifestations are a frequent reason for clinical trial inclusion. For example, in the phase III ILLUMINATE trial, 81% of patients had MSK activity at baseline [24]. Joint involvement in SLE is typically non-deforming and non-erosive. Jaccoud’s arthropathy (JA) is characterized by deformities in 5–15% of patients without radiographic erosions, whereas radiographic erosions may be detected in less than 5% of patients, suggesting the overlap between rheumatoid arthritis (RA) and SLE known as rhupus syndrome [25]. Comorbidities such as fibromyalgia (6–32%) [26, 27], fragility fractures (8–12%) [28, 29], and osteonecrosis (2–12%) [30] also contribute to MSK manifestations in SLE. Lupus arthritis is distinguished by a pattern of involvement that is typically, but not always, symmetric and that is localized in small joints. Because of the existence of joint effusion or synovial proliferation, the joints that are affected may appear to be swollen and/or reddened [25].
In the current study, about 71% of our cohort reported MSK symptoms in more than five body areas, and about half of them (49.5%) had MSK symptoms lasting for more than 3 months. These widespread and chronic MSK symptoms call into question the diagnosis of FM. Although FM is common in SLE patients, the condition is frequently underdiagnosed by physicians [31]. The widespread MSK pain and heightened sensitivity to pain are two of the most prominent symptoms of FM, which is a condition that can be debilitating on an emotional, social, and physical level [32]. FM can also be identified in patients with SLE, with the prevalence of the condition ranging from 8 to 61% [33, 34]. In fact, the prevalence of FM in Caucasian SLE patients is high compared to that of the general population, and it is significantly greater in patients who are in the later stages of the disease [26].
Bearing in mind that inflammatory MSK manifestations typically take the form of transient and migratory arthralgia (30–50%), fleeting arthritis (25–40%), or persistent arthritis (10–15%) [35], when we looked at the pain intensity in our cohort, we found only 19.4% with mild pain, while most of the patients described the pain as discomforting (40.8%). Several observations and reports have cast doubt on the idea that joint involvement in SLE is generally mild and only occasionally severe. This is a belief that has been questioned. One of the most frequent and incapacitating clinical manifestations that patients frequently describe is joint pain [36]. The presence of high pain scores in patients with SLE has been associated with a decline in quality of life, as well as fatigue, anxiety, and depression [37]. When viewed from a clinical standpoint, joint involvement can take place at any point throughout the course of the disease. It is distinguished by a wide variety of phenotypes and degrees of severity, ranging from mild arthralgia to erosive arthritis and causing significant functional disability [25, 38].
Despite the treatment that is currently available, individuals with SLE have a lower quality of life and a higher rate of work disability, and MSK symptoms are one of the strongest determinants of this [39, 40]. According to our findings, patients with MSK symptoms scored significantly worse in all domains than those without symptoms. In addition, the QoL scores of patients with more than 5 body sites of MSK symptoms were significantly lower than those of patients with fewer than 5 sites of MSK symptoms. According to a study conducted by Malcus Johnsson and colleagues, 73% of SLE patients struggle with hand difficulties that get in the way of their day-to-day activities [41].In addition, FM is a significant predictor of poorer self-reported quality of life in SLE patients, as has been previously demonstrated [42, 43].
This study has a number of limitations that need to be addressed. It’s possible that the results of the study were influenced by the way the data were collected, which relied mainly on self-reporting. The absence of a control group in this study is another limitation of this study. Additionally, it would be preferable if further research could identify the causes of these MSK manifestations and their predictors. Assessing the prevalence of FM in Egyptian patients with SLE would also be interesting. To evaluate the relationship between MSK manifestations and HRQoL in SLE patients, we recommend to compare them to a community-based control group.
In conclusion, the findings of this study indicate a high prevalence of MSK symptoms among SLE patients as well as a detrimental effect on HRQoL. The wrists and hands appear to be the most afflicted parts of the body. Further, longitudinal studies are required to investigate, identify, and treat MSK manifestations in SLE patients.
Acknowledgements
Not applicable.
Declarations
Ethics approval and consent to participate
The Institutional Research Board of the Faculty of Medicine at Mansoura University provided its approval (Approval No: R.23.04.2145). The work was conducted according to the principles mentioned in the Helsinki Declaration [44]. Participation in the study was completely voluntary and confidential. The objective of the study was explained in depth, and informed consent was obtained. In the case of participants who were illiterate or otherwise incapable of providing informed consent, parental or legal guardian consent was obtained.
Consent for publication
Not Applicable.
Competing interests
The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.